Delcath Systems (DCTH) vs Enovis (ENOV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Delcath Systems (DCTH) has outperformed Enovis (ENOV) over the past year, gaining 41.2% versus a loss of 43.6%. Over five years, DCTH leads with a +59.8% price change compared with -79.7% for ENOV. Enovis is the larger company by market cap ($1.02 billion vs $533.0 million), about 1.9 times the size.
On valuation, Enovis trades at a lower forward P/E (4.9x vs 341.3x for Delcath Systems).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DCTH | ENOV |
|---|---|---|
| Share price | $15.36 | $17.69 |
| Market cap | $532.97M | $1.02B |
| 1-day change | +2.13% | +1.49% |
| YTD return | +52.08% | -33.60% |
| 1-year return | +41.18% | -43.61% |
| 5-year return | +59.83% | -79.70% |
| Forward P/E | 341.33 | 4.93 |
| EPS (TTM) | $0.01 | $-19.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.42 | $34.28 |
| 52-week low | $8.12 | $16.70 |
| Distance from 52-week high | -11.83% | -48.40% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +56.25% | +112.44% |
| Average volume | 479.73K | 1.46M |
| Shares outstanding | 34.70M | 57.67M |
| Employees | 156 | 7,802 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DCTH has outperformed ENOV by 84.8 percentage points over the past year.
About Delcath Systems
DCTH stock →Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Health Care · Medical/Dental Instruments · 156 employees
About Enovis
ENOV stock →Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Health Care · Industrial Specialties · 7,802 employees
DCTH vs ENOV FAQ
Which is bigger, Delcath Systems or Enovis?
Enovis (ENOV) is larger, with a market capitalization of $1.02B compared with $532.97M for Delcath Systems (DCTH).
Which stock has performed better over the past year, DCTH or ENOV?
DCTH returned +41.18% over the past 12 months, compared with -43.61% for ENOV (price return, excluding dividends). Past performance does not predict future results.
Are Delcath Systems and Enovis in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Delcath Systems and Industrial Specialties for Enovis.